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tially simpler than the present network of medical aid schemes.
On the other hand, many of the social goals desired by the
proponents of nationalisation may well be achievable through
a national health insurance system.
We believe that it is an idea worth putting on the agenda for "-
debate, refmement, and negotiation.
We wish to thank our colleagues in the Centre for the Srudy of
Health Policy, in particular Max Price and Melvyn Freeman, for
comments on earlier draftS of this paper.
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The •maXImum medical aid •prIce programme
A review of the concept and of its ability to reduce
expenditure on medicines , .-
'.../ --.J
D. SOyeE, G. BARTLETT
Summary
Medicine prices in South Africa have increased significantly
in recent years. Furthermore, a consideration of expenditure
on medicines by medical schemes shows that this component
of health care costs had grown to 26,1% in 1988, which is
high by comparison with other Western economies. The use
of generic medicines offers one possible solution to rising
expenditure. For savings to be optimised, however, generics
need to be used on a planned and structured basis. The
maximum medical aid price (MMAP) system of the Pharma-
ceutical Society of South Africa provides such a programme.
MMAP is a programme through which certain medical
schemes elect to pay only a specified maximum price for off-
patent products that have generic equivalents. Although
MMAP does not require substitution by generic medicines, it
does have the effect of encouraging their use.
Two case studies measuring the savings that can be
achieved through adoption of MMAP by medical schemes
are reviewed. Although they differ in their respective
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methodologies, their results are consistent and show that
savings of about 9,3% were possible in 1989. Medical schemes
with higher proportions of older members tend to show
greater savings. The studies also show that the potential for
achieving savings through the use of MMAP increases with
the passage of time.
S Afr Med J 1990; 78: 147-151.
Medicine prices have increased significantly in recent years.
Over the past 5 years, the medicines price index has risen by
152,0% (20,3% per annum). The consumer price index (CPI)
increased by 108,4% (15,8% per annum) over the same 5-year
period. Thus the annual increase in medicine prices has
exceeded the annual increase in the CPI by an average of 4,5%
per year over the period 1984-1989.'
Expenditure on medicines by medical schemes in the private
sector in South Africa, already high at 25,3% in 1977, had
grown by 1988 to 26,1% of total expenditure.2 These figures
exclude the patient's contribution in the form of co-payments
and, in respect of many medical aid schemes, also exclude
expenditure on medicines for hospitalised patients. An accurate
estimate of aggregate expenditure on medicines in the private
sector would be closer to 30% of total expenditure. This
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compares with about 9% in the USA, 12% in the UK, and an
average of 16% for all EEC countries. 3,4 It is evident that the
relative expenditure on medicines in South Africa is consider-
ably higher than in other Western countries.
When cognisance is taken of the fact that medicine price
levels in South Africa are estimated to be 19,3% higher than in
the UK,5 it becomes apparent that the wide disparity in
expenditure between these two countries can only partially be
attributed to differences in their price levels. Of key signifi-
cance, then, are likely to be differences in patterns of utilisation
of medicines.
Utilisation has many facets: it is dependent. on factors
induding the incidence of morbidity, access to health services,
application of rational prescribing practices, patient expecta-
tions, and product selection. In respect of product selection, a
major trend in many countries has been a movement toward
the use of generic medicines. In the USA, for example, the
percentage of prescriptions written in generic (i.e. chemical)
terms was 36% in 1987.6
Generic medicines
In general terms, a generic medicine is an alternative (and
generally less expensive) brand of an ex-patented product of
original research. A generic equivalent, more specifically, is a
medicine that is chemically and pharmaceutically identical to
another. 7
Generic substitution is said to have taken place when a
generic equivalent product is dispensed instead of the original
brand of the product. Such 'substitution' may be performed
by the prescriber himself, at the time of prescribing, or he may
simply use the approved (generic, or chemical) name of the
product, leaving choice of brand to the dispenser: this is
referred to as generic prescribing.
Savings from the use of generics can be significant, as price
differences between generic products and their equivalent
original brands vary between 15% and 85%. A repon in
December 1988 (D. Boyce - unpublished data) showed that a
basket of generic products was 46,3% less expensive than a
comparable basket of original products. Table I illustrates
some of the recent price differences.
For optimum savings to be achieved, the use of generics
should take place on a planned and structured basis. This is
achieved in various ways in other countries; it may include the
use of a formulary or so-called 'positive list' as in France and
Italy,S or may take a form such as that of the maximum
acceptable cost system in use in the USA.9 Significant savings
have been reponed using such structured programmes.
In South Africa, generic substitution has been common
practice in State and provincial hospitals for a number of
decades. Although no studies on the savings achieved by
generic substitution in the public sector in South Africa have
been reponed, expenditure on medicines by the State consti-
tutes less than 10% of total public sector health expenditure. 10
The extent of these savings is dramatic when these figures are
compared with current medicines expenditure of approximately
30% in the private sector. It is recognised that these savings
cannot be attributed solely to the use of generic medicines: the
tender market itself is an imponant factor in reducing medi-
cines expenditure. evertheless, it is the very existence of
generic alternatives that makes tender purchasing as cost-
effective as it is.
In the private sector, the Pharmaceutical Society of South
Africa has developed the maximum medical aid price (MMAP)
programme in an attempt to facilitate savings. 11
The MMAP concept
MMAP is a programme through which certain medical schemes
elect to pay only a specified maximum price for off-patent
products that have generic equivalents.
It is analogous to the difference between the consultation
fee for general practitioners determined by the Medical Asso-
ciation of South Mrica and the medical scheme tariff (Scale of
Benefits) set by the Representative Association of Medical
Schemes. While the practitioner may charge the MASA fee,
the patient will only be reimbursed at the RAMS tariff.
The objectives of the MMAP programme are not to dictate
what is prescribed by the medical practitioner, but to limit the
amount that the medical scheme will be liable for. MMAP
specifies a maximum price: it does not specify a product or
brand to be supplied. However, it will tend to have the effect
of encouraging the use of generic products by the public.
The MMAP list
The list of MMAP maximum prices is issued every 6
months to participating medical schemes and pharmacies. This
list contains the generic names (e.g. diazepam) and the maxi-
mum reimbursable prices of approximately 80 products and
their available variants (e.g. different strengths and dosage
forms), respectivelyY All manufacturers are invited to tender
their products for inclusion in the list. The conditions set for
consideration in the tender selection process include that the
price quoted by the manufacturer will not be increased during
the subsequent 6-month period; that the product is registered
with the Medicines Control Council; that the product is
available nationally; that it is available in treatment pack sizes;




Ampicillin 250 mg capSUles
Methyldopa 250 mg tablets
Allopurinol 300 mg tablets
Co-trimoxazole adult tablets
Propranolol 40 mg tablets
Diazepam 5 mg tablets
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TABLE 11. EXAMPLES OF FOUR TYPICAL ENTRIES IN THE MMAP LIST
Maximum
"- dispensed
No. in Approved price before Product
list name Strength Form Pack prof. fee (R) examples
Allopurinol 100 mg Tablets 100 25,92 Lo-uric
Puricos
300 mg Tablets 30 23,07 Lo-uric
Puricos
Ethipurinol
5 Amoxycillin 250 mg Capsules 15 9,00 Rocillin
trihydrate 500 mg Capsules 15 16,50 Rocillin
125 mg/5 ml Syrup 100 ml 9,64 Moxypen
250 mg/5 ml Syrup 100 ml 16,60 Moxypen
21 Diazepam 2mg Tablets 100 6,00 Ciaquel
Ethipam
5 mg Tablets 100 6,00 Ciaquel
Ethipam
10mg Tablets 30 6,21 Pax
31 Furosemide 40mg Tablefs 30 8,30 Hydrex
(frusemide) Puresis
Aquasin
and that the product is backed by legal liability guarantees in
respect of quality.
The brand that sets the maximum price for any particular
product is selected on the basis of its competitive price,
although it may not necessarily be the lowest price tendered.
Other practical considerations may play a role in the selection.
For any particular product, therefore, several generic brands
usually fall within the maximum reimbursable price (Table
II).
It has been estimated that in 1988 the products on the
MMAP list represented approximately 20% of all prescription
items dispensed in the private sector. 13
MMAP in practice
Patients, pharmacists and, where applicable, doctors are
notified of a medical scheme's intention to implement MMAP,
and the modus operandi is explained. In an effort to gain co-
operation and support, the beneficial effects of cost savings to
the members of the scheme are explained. Members benefit
directly from reduced expenditure, reduced co-payments, and
a 'stretching' of their annual medicme allowances allowed by
their respective schemes.
In medical schemes where MMAP is established, medical
practitioners tend to prescribe generic products within the
maximum permitted price in an effort to be of assistance to
their patients. However, in the stage of adoption of the
MMAP programme by a scheme, before members and their
medical practitioners are acquainted with the scheme, it is not
uncommon for prescribers to prescribe products that are
priced higher than the MMAP price. In these instances the
patient has two options. He may accept the product prescribed
and pay the excess over the MMAP price. Alternatively, the
patient may decide to ask the medical practitioner to prescribe
a product within the MMAP price range. Often the pharmacist
is requested by the patient to perform this communication on
his behalf. Legally, the pharmacist may not substitute one
product for another without the prior permission of the
prescriber. 14
The growth of MMAP
MMAP was first implemented in 1985. Since then it has
become a significant feature of the medicines delivery system
in South Mrica. Certain major medical schemes have adopted
MMAP, as have the provincial authorities of the Transvaal,
the Orange Free State, and the Cape (in these latter cases, for
ambulatory patients).
Cost savings achieved by MMAP
Of great importance to medical scheme administrators and
other health care policy makers i~ the extent to which cost
savings occur using MMAP, and what factors may affect these
savings. The results of two case studies are discussed below.
Case study 1 - generic substitution and cost
savings in the OFS in 1985
This was the earliest implementation of the MMAP concept.
In 1985, the Provincial Hospitals Department of the OFS
Administration provided health services to ambulatory patients,
who are primarily State pensioners, by utilising the services of
district surgeons. Prescriptions written for these patients were
dispensed by private sector retail pharmacies throughout the
Province. In an effort to contain costs, the Administration
approved the implementation, in May 1985, of a programme
similar to the present MMAP programme, with the exception
that the compilation of the product list was not formalised in
the way it is today. ManufaCturers were not systematically
invited to tender for inclusion of their products on the list,
which contained generic brands that represented savings over
the prices of the equivalent original brands. In addition, where
pharmacists were able to obtain cost savings on listed products
through bulk purchasing, these savings were passed on to the
Province by the pharmacists. Initially the use of the listed
products was not compulsory for either prescribers or pharma-
cists.
Fig. 2. Trend in average cost per LAMAF prescription - MMAP
applied/not applied.
Oet Nav Dec Jan Feb Mar Apr May Jun Jul Aug Sap Oct
1988 1989 I
Claim Month
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An earlier paper by the authors investigated the success of
this programme in achieving savings;15 404 789 prescription
items dispensed during the 6-month period of the programme
were analysed, and 78 substitutable products were selected for
detailed analysis. Using baseline data from the period before
implementation of the programme, savings were defined as the
amount that would have been spent had the programme not
been implemented. The post-programme residual effects on
the prescribing habits of the doctor cohort were also examined.
The results showed that the 78 substitutable original-brand
products selected for analysis all lost market share to their
listed generic equivalents, though at varying rates and to
differing extents. The overall trend in the market share of
original brands is illustrated in Fig. 1, which shows the
gradual effects of the voluntary panicipation by members,
practitioners and pharmacists, the fact that maximum savings
had not yet been achieved at termination of the programme,
and the residual effect on prescribing in the first quarter of
1986.
By the 6th month of the programme, savings had reached
6,2% of overall expenditure; at this stage, savings had not yet
reached their full potential, which was calculated to be 11,5%.
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Fig. 1. Overall trend in market share of substitutable original
brands, OFS 1985.
Case study 2 - the impact of MMAP on the
Local Authorities Medical Aid Fund (LAMAF)
in 1988/89
LAMAF is a private-sector scheme for municipal employees
in the Cape Province. Before implementation of MMAP the
average price of a LAMAF prescription was 8,3% above the
private sector national average. MMAP was implemented by
LAMAF in October 1988.
In a study of the first 5 months of operation of MMAP,
110000 prescriptions were analysed. 13 Trends in average
prescription prices of LAMAF prescriptions were compared
with trends in non-LAMAF prescriptions. The difference
between these trend-lines was used to obqlin an estimated
value for LAMAF prescriptions had MMAP not been applied.
This, in turn, was used to calculate the percentage savings


















The authors show that the average cost of a LAMAF
prescription dropped sharply when MMAP was introduced
and fell to below the national average prescription price.
Furthermore, they show that the savings achieved by the
scheme over the initial 5-month period represented 7,9% of its
.anticipated expenditure had MMAP not been introduced.
Analysis of the impact of MMAP on the expenditure by
LAMAF on medicines for the first 12 months of the pro-
gramme - October 1988 - September 1989 - shows that
S2vingS during this period were 9,3% (Fig. 3).16 It should also
be noted that the average cost of a LAMAF prescription rose
more slowly than that of other prescriptions.
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Although the two studies reviewed in this paper differ
somewhat in methodology, both show that MMAP is able to
effect significant savings in medicines expenditure for large
patient groups.
Case study 2, conducted in 1988/89, shows overall savings
for the medical scheme concerned of 9,3% of projected expen-
diture on medicines. Case study 1, which was based on a
sample of patients with a markedly different demographic
profile, showed a potential saving of 11,5%, although the
actual saving achieved was 6,2%. Failure to reach potential
savings was due to the policy of voluntary participation (see
below) and the fact that the programme was prematurely
terminated.
Age/membership profile
Age distribution of medical scheme membership is the
single most important factor in determining the scheme's
potential savings from MMAP. Case study 2 was based on a
private sector medical scheme which provided services to
members as well as to their families. Age distribution within
this scheme resembled that of the total white population and,
as such, would have contained a proportion of aged members.
However, in the first case study, all patients were old-age pen-
sioners; dependants - and children in particular - were
excluded. The aged have a higher incidence of chronic condi-
tions requiring long-term medication, and many generic
(MMAP) medicines are available in these therapeutic classes.
The savings on these long-term treatments are significantly
higher than savings in respect of short-term treatments. Hence
the savings (potentially 16,1% in 1988) achieved by MMAP in
the OFS geriatric sample could be expected to be higher than
those achieved in the other case study. Similarly, at an indivi-
dual patient level, and in medical schemes, older patients have
more opportunity than younger people to obtain savings on
their prescription purchases when using MMAP.
The passage of time
The savings that can be achieved using MMAP increase
with the passage of time for a number of reasons. Firstly,
product patents continue to expire each year and such products
become susceptible to competition from generic equivalent
products; the variety of generic products available therefore
continues to increase annually. Secondly, with the prospect of
an expanding market for generic products, new generic manu-
facturers enter this market, thereby increasing the number of
available generic products and the competition between these
products. Thirdly, increasing pressure on the budgets of third-
party payers in a price-sensitive market provides an opportunity
for expansion of the generic market. These factors result in
increasing price competition, cheaper generics, and larger
potential savings.
Mandatory v. voluntary participation
The time taken to reach optimal savings using MMAP is
influenced by whether participation is voluntary or mandatory.
As is evident in case study 2, mandatory implementatiqn of
MMAP results in immediate savings at the maximum potential
level. Voluntary participation, on the other hand (as in case
study I), results in a more gradual increase in savings that may
take some time to reach its maximum level, and is likely to be
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less than that which could be achieved with mandatory
participation.
" Rational therapeutics
Although not inherent in MMAP, the authors believe that
the use of MMAP is likely to heighten medical practitioners'
awareness of their prescribing habits. Patients also become
more aware of the choice of prescribed product, and its price.
It is probable that the prescriber under these conditions will
prescribe more thoughtfully, more rationally, and with an
increased awareness of cost.
Conclusion
The studies reviewed show that MMAP provides a viable
option for administrators of medical schemes and other health
care managers to effect significant savings in expenditure on
medicines. These savings, in respect of a large group of people
of normal age distribution, were of the order of 9,3% in 1989.
A saving in excess of 16% in 1988 could have been anticipated
in groups with a higher proportion of older people.
In addition, the studies show that the potential savings in
any given group tend to increase with the passage of time.
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